FDA Investigator Tara C Singh
Tara C Singh has conducted inspections on 98 sites in 3 countries as of 26 Aug 2013. See below for a list of the FDA enforcement documents resulting from those inspections.
Investigator Details
Number of Inspected Sites:
98
Last Inspection Date:
26 Aug 2013
Investigator Role:
FDA Investigator
Redica ID:
Countries of Inspections:
United States of America,
India,
China
FDA Investigators that have inspected at least one site in common with Tara C Singh:
Aaron L Dunbar,
Aimee J Edwin,
Alan R Albrecht,
Alison A Nicoli,
Althea A Williams,
Amber M Capello Jones,
Amy L Mcintyre,
Andrea B Slavin,
Anthony L Nicoli,
April L Young,
Benjamin W Anderson,
Billi Jom Johnson,
Boun M Xiong,
Bradley A Servais,
Carol Rivera Lopez, PhD,
Carolyn A Warren,
Catherine M Vanderhoef,
Christina A Castineyra,
Christine M Erickson,
Constance L Richard,
Corey K Reno,
Courtney R Tiegs,
Craig R Berger,
Dacia E Quick,
Dale A Nyberg,
Darlene L Krieger,
Darren D Holaday,
David B Wieneke,
Dayle Radde,
Demetria L Lueneburg,
Denise L Burosh,
Diane T Reindl,
Dianna C Sonnenburg,
Douglas J Snyder,
Douglas W Atkins,
Dr. Gopa Biswas, PhD,
Dr. Hansong Chen, PhD,
Duc Minh H Nguyen,
Edward A Fabiano,
Elizabeth E Hart (ASCP), MT,
Elizabeth P Mayer,
Ellen C Weisensel,
Eric S Myskowski,
Fannie M Harrell,
Frank S Sedzielarz,
Frederick J Tillman,
Garrett W Steiner,
Gina M Scholze,
Grant M Ruis,
Gregory S Larson,
Gregory W Smith,
Heather Akleimola Hulbert,
Howard A Burmester,
Ivan E Reyes,
Jaclyn N Munsch,
Jake T Lane,
James R Evans,
Jan L Hewett,
Jane E Nelson,
Janis R Armedoriz,
Jasjeet K Sekhon,
Jean M Bosenbecker,
Jeffery A Hangartner,
Jennifer A Longie Vollom,
Jennifer Guttuso,
Jennifer S Ness,
Jeremy L Tri,
Jesse P Romenesko,
Jessica L Johnson,
Jessica M Novak,
Jocelyn M Muggli,
John E Emmert,
Jonell R O'neil,
Joseph D Gong,
Joseph J Golden,
Joseph M Edwin,
Julie Woodberry,
Jyoti B Patel, PhD,
Karen M Labounty,
Karla J Youngberg,
Katherine A Clarke Girolamo,
Kellie L Thommes, RN,
Kellie L Westerbuhr,
Kenneth A Libertoski,
Kimberly W Destromp,
Krista K Petersen,
Kristy E Zuroski,
Kyle J Mccracken,
Lauren E Sanger,
Leonardm,
Linda V Weyer,
M Edith Snyder,
Mada A Tautges,
Madeline T Campbell,
Margaret M Lubbers Solberg,
Margaret M Solberg,
Maria E Kuhn,
Maria E Treadwell,
Marie A Fadden,
Marissa S Steinhagen,
Mary M Finn,
Melissa D Kalik,
Melissa I Michurski,
Melissa J Holz,
Michael E Cimaglio,
Mohammed H Adam,
Nicole C Victoria, PhD,
Paola E Lathrop,
Patricia A Holmstrom,
Patrick J Campbell,
Peter T Erlandson,
Ralph Jerndal,
Rebecca L Caulfield,
Rebecca L Keller,
Rebecca L Mullikin,
Robert H Claflin,
Robert J Waldorf,
Sana A Elassar,
Sandra Sejdinovic,
Sarah A Palmer,
Sarah Nwandiuko,
Scott B Laufenberg,
Scott L Schenian,
Sharon L Matson,
Sharon M Harold,
Shaun M Olson,
Sripal R Mada, PhD,
Steven A Skaar,
Susan M Matthias,
Tara M Carolfi,
Theresa C Klaman,
Thomas S Donaldson,
Tony T Yang,
Traci C Kelm,
Tracy A Solseng,
Tyler R Courtney,
Wendy L Trefethren Grang,
William E Keer,
Xikui Chen (nmi), PhD,
Yehualashet A Gessesse,
Zachary P Wachlarowicz
Tara C Singh's Documents
| Publish Date | Document Type | Title |
|---|---|---|
| June, 2012 | FDA 483 | Fleming, John O., MD, Sponsor-Investigator - Form 483, 2012-06-15 |
| March, 2013 | EIR | Sastry, Bhagavatula K. S., MD, Clinical Investigator - EIR, 2013-03-21 |
| June, 2012 | EIR | Fleming, John O., MD, Sponsor-Investigator - EIR, 2012-06-15 |
| July, 2012 | EIR | Bellin Health System Inc., IRB - EIR, 2012-07-25 |
| October, 2012 | FDA 483 Response | 3M Company IRB - Form 483R, 2012-10-22 |
| December, 2009 | FDA 483 | Mid-states Closeouts, Inc - Form 483, 2009-12-21 |
| October, 2011 | EIR | U Of MN Research Subjects' Protection Program/ IRB - EIR, 2011-10-18 |
| July, 2012 | FDA 483 | Bellin Health System Inc., IRB - Form 483, 2012-07-25 |
| March, 2013 | EIR | Zeng, Xiaofeng, MD, Clinical Investigator - EIR, 2013-03-15 |
| September, 2012 | FDA 483 | Medtox Laboratories, Inc. - Form 483, 2012-09-14 |
| September, 2011 | EIR | PRACS Institute, Ltd. - EIR, 2011-09-16 |
| October, 2012 | FDA 483 | 3M Company IRB - Form 483, 2012-10-22 |
| September, 2012 | EIR | Medtox Laboratories, Inc. - EIR, 2012-09-14 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more